Who We Are

Ellis Neufeld, MD PhD
Program Director
Children's Hospital Boston

Dr. Ellis Neufeld earned his Bachelor’s degree in Chemistry and Biology from Wesleyan University in Middletown, Connecticut, in 1979, and his MD, PhD, in Medicine, Biochemistry, and Molecular Biology from Washington University School of Medicine in St. Louis, Missouri, in 1985. Dr. Neufeld spent his internship and residency at the Children’s Hospital Boston. He also spent his fellowship at CHB, where he was Fellow in Clinical Genetics, 1988, and Fellow in Hematology/Oncology from 1998-1990. Dr. Neufeld's bench-to-bedside research focuses on thiamine-responsive megaloblastic anemia (TRMA) syndrome, a rare inherited early-onset disorder that leads to anemia, diabetes, and progressive deafness, but can be ameliorated with high doses of thiamine (vitamin B1). Dr. Neufeld’s clinical research activities are numerous, including his role as Principal Investigator for two NHLBI clinical research network grants—the Transfusion Medicine Hemostasis Network and the Thalassemia Clinical Research Network. He also holds a K24 Mid-Career Investigator Award to support his mentoring activities in patient-oriented research. Dr. Neufeld currently serves as Associate Chief of the Hematology/Oncology Division of the Children’s Hospital Boston and Director of the Boston Hemophilia Center, and is the Egan Family Foundation Professor of Pediatrics at Harvard Medical School.

Meghan Sullivan
Program Coordinator
Children's Hospital Boston

Meghan Sullivan has been working in the Hematology Division of the Children's Hospital Boston for over three years. She received her B.A. in English from Bridgewater State College and is currently working on obtaining her Master of Social Work from Simmons College. She enjoys volunteering at Camp Sunshine in Casco, ME which is a retreat for children with life-threatening illnesses and their families.

Kenneth Bauer, MD
Beth Israel Deaconess Medical Center
Adult Hematology, Thrombosis/Hemostasis

Dr. Kenneth Bauer is Professor of Medicine, Harvard Medical School. His hospital positions include Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical Center and Chief, Hematology Section, VA Boston Healthcare System. Dr Bauer received his medical degree from Stanford University School of Medicine in Stanford, California. He completed his residency in medicine at the University of Chicago Hospitals and Clinics in Illinois. He was a Fellow in Medical Oncology and a Clinical/Research Fellow in the Division of Thrombosis and Hemostasis at Dana Farber Cancer Institute and was also a Clinical/Research Fellow in the Hematology-Oncology Division at Beth Israel Hospital, Boston, Massachusetts. Dr Bauer’s research interests include development and clinical evaluation of sensitive new assays for the detection of hypercoagulable states, definition and elucidation of the mechanisms leading to the development of a prethrombotic state, and clinical evaluation of new antithrombotic drugs. Dr Bauer served as immediate past-Chairman of the Council of the International Society on Thrombosis and Haemostasis (ISTH) and was previously Chairman of the Subcommittee on Predictive Haemostatic Variables in Vascular Diseases of the ISTH. Dr Bauer has published over 200 original reports, reviews, and book chapters.

Leslie Silberstein, MD
Center for Blood Research Institute
Pediatric and Adult Transfusion Medicine

Dr. Leslie Silberstein received the Baccalaureate and M.D. Degrees from the University of Leiden, the Netherlands, and had post-graduate training in Hematology/Oncology and Transfusion Medicine at Tufts-New England Medical Center in Boston, MA. He is currently a Professor of Pathology at Harvard Medical School and Director of the Joint Program in Transfusion Medicine at Children's Hospital, Boston, Brigham and Women’s Hospital, and the Dana-Farber Cancer Institute. He is also a Senior Investigator and Director of the Center for Human Cell Therapy at the CBR Institute for Biomedical Research. The overall theme of Dr. Silberstein’s research laboratory pertains to the role(s) of chemokines in the bone marrow environment. This research is funded in part by a program project grant, “Adhesion Molecules in Transfusion Medicine”, of which Denisa Wagner is the principal investigator.

Ellis Neufeld, MD, PhD
Children's Hospital Boston
Pediatric Hematology, Pediatric and Adult Hemophilia and Thalassemia

Edward Benz, MD/James Griffin, MD, co-Site Directors
Dana Farber Cancer Institute
Adult Hematology, Red Cell Biology, Growth Factor Biology

Dr. Edward J. Benz, Jr is president and chief executive officer of Dana-Farber Cancer Institute and Dana-Farber/Partners Cancer Care as well as Principal Investigator and Director of Dana-Farber/Harvard Cancer Center and a member of the Governing Board of Dana-Farber/Children's Hospital Cancer Center. He is also the Richard and Susan Smith Professor of Medicine and a Professor of Pediatrics, and Professor of Pathology at Harvard Medical School. He is a graduate of Princeton University and Harvard Medical School. An internationally recognized hematologist, Dr. Benz received his training at Brigham and Women's Hospital and the National Institutes of Health. Board certified in internal medicine and hematology, Dr. Benz is an expert in inherited anemias and diseases of the red cell, and the red cell membrane cytoskeleton. Dr. Benz is president-elect to the Association of American Cancer Institutes and is currently the co-chair of the NIH Advisory Board for Clinical Research. He continues to be an active NIH funded investigator whose laboratory studies the molecular pathology of red cell disorders. He is the author of over 200 scientific books, papers, and abstracts.

David Kuter, MD, DPhil
Mass. General Hospital
Adult Hematology, Thrombosis and Hemostasis

Dr. David J. Kuter earned a research doctorate (DPhil) at Magdalen College of Oxford University and a medical degree at Harvard Medical School. Dr. Kuter holds appointments as Associate Professor of Medicine at Harvard Medical School and Associate Professor of Health Sciences and Technology at the Massachusetts Institute of Technology. Dr. Kuter is board certified in internal medicine, hematology, and medical oncology. Dr. Kuter has research efforts researching coagulopathies, anticoagulation, and platelet disorders. In recent years, Dr. Kuter has conducted basic and clinical research into the development of effective thrombopoietic agents. He is Director of Clinical Hematology at the Massachusetts General Hospital, Director of the MGH Gaucher’s Treatment Center, and Program Director for Hematology at MGH/Partners/DFCI. He has overseen hematology training for the Hematology/Oncology Fellows at MGH for over two decades.

Nancy Berliner, MD
Brigham and Women's Hospital

Dr. Berliner earned her Bachelor’s degree from Yale College and her MD from Yale Medical School. She then obtained training as a Resident in Internal Medicine, Internal Medicine Chief Resident, and Hematology Fellow at the Brigham and Women’s Hospital in Boston, MA. She then spent 20 years on the faculty of the Yale University School of Medicine, where she rose through the ranks to Professor of Internal Medicine and Genetics. In January, 2007, Dr. Berliner returned to the Brigham where she is Chief of Hematology and Professor of Medicine at Harvard Medical School. Dr. Berliner has broad clinical interests in both classical hematology and hematologic malignancies. Her research is focused on the regulation of neutrophil-specific gene expression and its disruption in myelodysplasia and acute leukemia. More recently she has also initiated studies of the role of inflammatory cytokines in the pathogenesis of anemia in the elderly. She is currently Vice President of the American Society of Hematology, and will be ASH President in 2009.

David G. Nathan, MD
Dana-Farber Cancer Institute, Children’s Hospital
Aplastic Anemias, Hemoglobinopathies and Hemolytic Anemias

Dr. David G. Nathan is a graduate of Harvard College (1951) and Harvard Medical School (1955). He was an intern and senior resident in medicine at the then Peter Bent Brigham Hospital and a Clinical Associate at the National Cancer Institute. From 1959 to 1966 he was a hematologist at the Peter Bent Brigham Hospital and then became Chief of the Division of Hematology and Oncology at Children's Hospital and Dana-Farber Cancer Institute. From 1985 to 1995 he was Physician-in-Chief of the Children's Hospital and from 1995 to 2000 was President of Dana Farber Cancer Institute. Dr. Nathan's research has focused on the inherited disorders of red cells and granulocytes and particularly on thalassemia. He has trained over 100 hematologists many of whom hold leading positions in pediatrics and internal medicine. His text book entitled Hematology of Infancy and Childhood is the leading text in the field. He is the author of two popular books: Genes Blood and Courage published by the Harvard University Press in 1995, and Smart Drugs: Attacking Cancer in the 21st century, to be published by John Wiley in 2007. Dr. Nathan is a member of the American Society for Clinical Investigation, the Association of American Physicians, the American Pediatric Society, the Institute of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society.

Peter Newburger, MD
UMass Memorial Medical Center

Dr. Peter Newburger earned his B.S. degree in chemistry from Haverford College, Haverford, PA, in 1970, and his MD from Harvard Medical School (cum laude in immunology) in 1974. After internship and residency at Children’s Hospital, Boston, he trained in pediatric hematology and oncology at the (then) Sidney Farber Cancer Center and Children’s Hospital, Boston from 1976 to 1979. He served on the faculty at Harvard Medical School and Children’s Hospital for two years, then moved to the University of Massachusetts Medical School in 1981 to establish the medical center’s first pediatric hematology/oncology division, which he has directed since 1981. He is currently the Ali and John Pierce Professor of Pediatric Hematology/Oncology, as well as Vice Chair and Director of Research for the Department of Pediatrics, at UMass Medical School. He has served as a member of NIH hematology study sections virtually every year since 1986. He is a member of the Sub-Board of Pediatric Hematology/Oncology of the American Board of Pediatrics, associate editor of Pediatric Blood and Cancer, and member of the editorial boards of Blood (past), American Journal of Hematology, and Current Opinion in Hematology. His laboratory research focuses on leukocyte gene expression and disorders of phagocyte function, and he directs clinical research on neutropenia through membership on the executive committee of the Severe Chronic Neutropenia International Registry.

Kenneth A. Bauer, MD
Beth Israel Deaconess
Disorders of Hemostasis, Thrombophilia and Venous Thrombosis

David J. Kuter, MD DPhil
Massachusetts General Hospital
Disorders of Hemostasis, Thrombophilia and Venous Thrombosis

Leslie E. Silberstein, MD
CBR Institute, Children’s Hospital, Joint Program in Transfusion Medicine
Pediatric Transfusion Medicine and Cell–based Therapies

Richard M. Stone, MD
Dana-Farber Cancer Institute
Myeloproliferative Disorders and Myelodysplastic Syndromes

Dr. Richard Maury Stone is Clinical Director of the Adult Leukemia Program at the Dana-Farber Cancer Institute, an attending physician at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Dr. Stone cares for patients with acute and chronic leukemias, myelodysplasia and myeloproliferative disorders. Dr. Stone conducts clinical and translational research with the goal of deriving better outcomes for patients with these disorders. His laboratory research focuses on the mechanism of leukemic cell differentiation, with the ultimate goal of producing new cancer therapies. Dr. Stone earned his AB in Biochemistry at Harvard Medical College in Cambridge, Massachusetts and his MD at Harvard Medical School in Boston. After graduating, he completed his internship and residencies in Internal Medicine at Brigham and Women’s Hospital in Boston, where he was designated Chief Medical Resident. Dr. Stone trained as a Fellow in Medical Oncology at the Dana-Farber Cancer Institute.

Leslie Kalish, ScD, ex officio
Biostatistics core, Clinical Research Program Children’s Hospital
Biostatistics, Training

Dr. Leslie Kalish’s professional career has focused on the design, implementation and analysis of clinical trials, epidemiologic studies, and other clinical investigations. His statistical research has been in the application of optimal statistical design methodology to treatment allocation procedures for clinical trials and to selection of control groups in observational epidemiologic studies. Dr. Kalish has collaborated on research in transfusion medicine, HIV and infectious diseases, immunology, oncology, alternative medicine, and other fields. He had leadership roles in the coordinating centers of several NIH-funded cohort studies and clinical trials, including as the original principal investigator of the coordinating center of the Transfusion Medicine/Hemostasis Clinical Trials Network. Dr. Kalish joined the Clinical Research Program at Children's Hospital Boston in 2003, where he continues to provide mentoring and analytic expertise to researchers in study design, protocol development, and grant-writing. He conducts or directs statistical data analyses for a variety of projects.